Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 17/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008645 | 0.91 | ADORA1 (0.61) | ADORA1ADORA3ADORA2BKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5007734 | 0.88 | ADORA1 (0.67) | ADORA1ADORA3ADORA2B | |
| SCHEMBL5008368 | 0.82 | ADORA1 (0.66) | ADORA1ADORA3ADORA2BKDM4E | |
| Trifluoroacetic Acid SCHEMBL5008642 | 0.80 | ADORA1 (0.73) | ADORA1ADORA3ADORA2B | |
| SCHEMBL5012017 | 0.78 | ADORA1 (0.68) | ADORA1ADORA3ADORA2B | |
| SCHEMBL5008331 | 0.78 | ADORA1 (0.72) | ADORA1ADORA3ADORA2BKDM4EALDH1A1 | |
| SCHEMBL3304814 | 0.75 | ADORA1 (0.84) | ADORA1ADORA3ADORA2B | |
| SCHEMBL5090418 | 0.72 | ADORA1 (0.71) | ADORA1ADORA3ADORA2B | |
| SCHEMBL1819219 | 0.72 | ADORA1 (1.00) | ADORA1ADORA3ADORA2B | |
| SCHEMBL5010629 | 0.71 | ADORA1 (0.82) | ADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA3 111/4885ADORA2B 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.